TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9439150

Group type: EXPERIMENTAL
Intervention: Levamisole added to chemotherapy (5-fluorouracil 1,000 mg/m2/day for 5 days and cisplatin 60 mg/m2 for 1 day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-levamisole group (5-fluorouracil 1,000 mg/m2/day for 5 days and cisplatin 60 mg/m2 for 1 day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Levamisole added to chemotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-levamisole group
Number of subjects: 100
Study: 8507222

Group type: EXPERIMENTAL
Intervention: Aspirin in RA patients
Number of subjects: 1616

Group type: EXPERIMENTAL
Intervention: Diclofenac in OA patients
Number of subjects: 1616

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1616

Group type: EXPERIMENTAL
Intervention: Aspirin in OA patients
Number of subjects: 1616
Study: 3565302

Group type: EXPERIMENTAL
Intervention: 25 g xylitol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose, fructose, or sucrose preload
Number of subjects: 0
Study: 30376088

Group type: EXPERIMENTAL
Intervention: IPV
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: IPV with bOPV
Number of subjects: 333

Group type: COMPARATOR
Intervention: No vaccine
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: All arms (A, B, C)
Number of subjects: 333
Study: 27404643

Group type: EXPERIMENTAL
Intervention: Spice MyPlate intervention (6-week school-based intervention focusing on cooking with spices and herbs)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard nutrition education (control group)
Number of subjects: 110
Study: 24764677

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) - 3 times weekly for 3 months, including exercises like leg press, chest press, seated rowing, latissimus pull down, with 8-12 repetitions, 3 sets for each exercise, total duration of 40 min.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (Stretching) - Home stretching for 3 months.
Number of subjects: 82
Study: 22945703

Group type: EXPERIMENTAL
Intervention: Amorphous Calcium Phosphate (Aegis‐ Opaque White, Bosworth Co. Ltd.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluoride containing (Teethmate F1 Natural Clear, Kuraray Co. Ltd.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Resin based (Concise‐ Opaque White, 3M ESPE Co. Ltd.)
Number of subjects: 30
Study: 20101197

Group type: EXPERIMENTAL
Intervention: Continuous heparin at 10 units/kg/hr
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Continuous heparin at 10 units/kg/hr (aged <30 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (aged <30 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Catheters in place > or = 7 days
Number of subjects: 90
Study: 18662199

Group type: EXPERIMENTAL
Intervention: Donepezil (vendor-supported trials)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Donepezil (non-vendor-supported trials)
Number of subjects: 18
Study: 16000966

Group type: EXPERIMENTAL
Intervention: REST routine treatment group
Number of subjects: 164

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 164
Study: 14518795

Group type: EXPERIMENTAL
Intervention: Free load lifting (light, medium, heavy)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Isokinetic lifting (slow, medium, fast)
Number of subjects: 13
Study: 10759091

Group type: EXPERIMENTAL
Intervention: Propranolol (80 to 400 mg/day)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 8828525

Group type: EXPERIMENTAL
Intervention: Topical application of H1-receptor antagonist (azelastine)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1520649

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion at 9.25 micrograms/kg/min over 24 hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6335859

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo TNS (transcutaneous nerve stimulation)
Number of subjects: 13
Study: 30840623

Group type: EXPERIMENTAL
Intervention: MCI with frontal-executive dysfunction (FED)
Number of subjects: 85

Group type: COMPARATOR
Intervention: MCI without frontal-executive dysfunction (FED)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Cognitively normal elderly (CNE)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: MCI groups (both with and without FED)
Number of subjects: 85

Group type: COMPARATOR
Intervention: CNE group
Number of subjects: 85
Study: 29209783

Group type: EXPERIMENTAL
Intervention: Aerobic exercise session
Number of subjects: 22

Group type: COMPARATOR
Intervention: Reference session
Number of subjects: 22
Study: 26986995

Group type: EXPERIMENTAL
Intervention: Gentamicin 5 mg kg(‐1) intravenous (i.v.) every 36 h
Number of subjects: 96

Group type: COMPARATOR
Intervention: Traditional dosage of gentamicin
Number of subjects: 96
Study: 23427280

Group type: EXPERIMENTAL
Intervention: Ranolazine 375 mg twice daily orally plus intravenous amiodarone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intravenous amiodarone alone
Number of subjects: 41
Study: 22993421

Group type: EXPERIMENTAL
Intervention: 20 mg of MPH
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20171613

Group type: EXPERIMENTAL
Intervention: Vitrification/warming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow-rate freezing/thawing
Number of subjects: 0
Study: 17919329

Group type: EXPERIMENTAL
Intervention: Telepsychiatric assessment
Number of subjects: 37

Group type: COMPARATOR
Intervention: Face to face interviews
Number of subjects: 37
Study: 16289796

Group type: EXPERIMENTAL
Intervention: Profile of Chronic Pain: Extended Assessment Battery (PCP:EA)
Number of subjects: 0
Study: 12176866

Group type: EXPERIMENTAL
Intervention: Peripheral blood
Number of subjects: 228

Group type: COMPARATOR
Intervention: Bone marrow
Number of subjects: 228
Study: 10454703

Group type: EXPERIMENTAL
Intervention: Maternal intravenous infusion of amino acids (Freamine 8.5% III, Baxter)
Number of subjects: 26
Study: 8554929

Group type: EXPERIMENTAL
Intervention: Stethoscope auscultation (SBPa, DBPa‐IV, DBPa‐V)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Stethoscope auscultation (DBPa‐IV)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Stethoscope auscultation (DBPa‐V)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oscillometry (SBPo)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oscillometry (DBPo)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Finger pulse pressure (DBPf)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Finger pulse pressure (SBPf)
Number of subjects: 8
Study: 2316590

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg) every 4 hours
Number of subjects: 31
Study: 6299842

Group type: EXPERIMENTAL
Intervention: High dosage vaccine
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Low dosage vaccine
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Vaccinated patients
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Patients with recurrent herpetic disease
Number of subjects: 121
Study: 31747967

Group type: EXPERIMENTAL
Intervention: Left-anodal tDCS (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Right-cathodal tDCS (n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham tDCS (n = 20)
Number of subjects: 60
Study: 30045711

Group type: EXPERIMENTAL
Intervention: DREAMS intervention
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: DREAMS+PrEP
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control (before DREAMS implementation)
Number of subjects: 1500
Study: 26801759

Group type: EXPERIMENTAL
Intervention: AFLY5 intervention
Number of subjects: 2221

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2221
Study: 24388327

Group type: EXPERIMENTAL
Intervention: iNO + vitamin A
Number of subjects: 793

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 793

Group type: COMPARATOR
Intervention: iNO
Number of subjects: 793
Study: 21654314

Group type: EXPERIMENTAL
Intervention: Enzastaurin (loading dose of 500 mg, followed by 250 mg daily) and Sunitinib (50 mg/d for 4 weeks)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Enzastaurin (loading dose of 1125 mg, followed by 500 mg daily) and Sunitinib (50 mg/d for 4 weeks)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Enzastaurin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 17
Study: 19327620

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of isosorbide dinitrates and hydralazine (FDC I/H)
Number of subjects: 352
Study: 17533403

Group type: EXPERIMENTAL
Intervention: PVACEBOP multi-agent chemotherapy as primary therapy for high-risk patients (SNLG index >or=0.5)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard ChlVPP or ABVD chemotherapy+/−radiotherapy for standard risk patients (SNLG index <0.5)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Not applicable (salvage therapy)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Not applicable (overall survival)
Number of subjects: 55
Study: 16447051

Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone once daily for 5 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 14631456

Group type: EXPERIMENTAL
Intervention: Diazepam, 15 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 11085962

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 404

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 404
Study: 8856156

Group type: EXPERIMENTAL
Intervention: Icatibant 3000 micrograms t.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Icatibant 900 micrograms t.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1503435

Group type: EXPERIMENTAL
Intervention: Intranasal pirodavir (2 mg per dose, 6 times per day for a total of 25 doses)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Hydroxypropyl-beta-cyclodextrin vehicle (placebo)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intranasal pirodavir (2 mg per dose, 3 doses daily)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intranasal pirodavir (24 h after RV challenge)
Number of subjects: 25
Study: 6384282

Group type: COMPARATOR
Intervention: Intralesional IFN‐alpha
Number of subjects: 10

Group type: COMPARATOR
Intervention: Systemic IFN‐alpha
Number of subjects: 10
Study: 29135501

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia in addition to standard care
Number of subjects: 386

Group type: COMPARATOR
Intervention: Control treatments only
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 386
Study: 28236571

Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Multiple daily injection (MDI) therapy
Number of subjects: 81
Study: 25053758

Group type: EXPERIMENTAL
Intervention: Bipedicle conjunctival flap (CF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cryopreserved amniotic membrane graft (AMG)
Number of subjects: 40
Study: 24030945

Group type: EXPERIMENTAL
Intervention: Kisspeptin-54 (6.4 nmol/kg, twice-daily subcutaneous injections during menstrual days 7-14)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 10
Study: 20348438

Group type: EXPERIMENTAL
Intervention: Late microvascular obstruction (MO)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Early microvascular obstruction (MO)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Baseline infarct volume index
Number of subjects: 100
Study: 17805229

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3 g day(-1), fish oil capsules)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (only capsules)
Number of subjects: 52
Study: 16148211

Group type: EXPERIMENTAL
Intervention: Enhanced counseling session
Number of subjects: 77

Group type: COMPARATOR
Intervention: General health information control session
Number of subjects: 77
Study: 12790209

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Midazolam-sufentanil
Number of subjects: 20
Study: 10891632

Group type: EXPERIMENTAL
Intervention: Naltrexone/Lofexidine combination treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional Lofexidine treatment
Number of subjects: 22
Study: 9023716

Group type: EXPERIMENTAL
Intervention: Perindopril and indapamide
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Perindopril alone
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 6000
Study: 1893706

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 35 ug plus norethindrone 0.4 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 30 ug ethinyl estradiol plus 1.5 mg norethindrone acetate
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: spironolactone 200 mg daily
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 30 ug plus 1.5 mg norethindrone acetate
Number of subjects: 51
Study: 6228504

Group type: EXPERIMENTAL
Intervention: Preparation A
Number of subjects: 44

Group type: COMPARATOR
Intervention: Preparation B (comparison group)
Number of subjects: 44
Study: 27734203

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 256

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 256
Study: 24415559

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM) with InterStim Therapy
Number of subjects: 147

Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Device-related adverse events
Number of subjects: 147

Group type: COMPARATOR
Intervention: Medication-related adverse events
Number of subjects: 147
Study: 24055014

Group type: EXPERIMENTAL
Intervention: IPX066 145 mg TID
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: IPX066 245 mg TID
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: IPX066 390 mg TID
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: IPX066 (all dosages)
Number of subjects: 381
Study: 22776850

Group type: EXPERIMENTAL
Intervention: Resveratrol triphosphate (RTP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Catechin-rich grape seed extract (CGSE)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Resveratrol (RES)
Number of subjects: 32
Study: 20015903

Group type: EXPERIMENTAL
Intervention: Topical intranasal corticosteroids (Mometasone furoate 50 microg)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 217
Study: 17538170

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (vinorelbine plus cisplatin)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 172
Study: 15293483

Group type: EXPERIMENTAL
Intervention: TENS and exercise training
Number of subjects: 62

Group type: COMPARATOR
Intervention: TENS
Number of subjects: 62

Group type: COMPARATOR
Intervention: Exercise training
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 62
Study: 11215868

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9147422

Group type: EXPERIMENTAL
Intervention: Two-drug regimen (clarithromycin 500 mg twice daily and ethambutol 800-1,000 mg daily)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Three-drug regimen (clarithromycin 500 mg twice daily, ethambutol 800-1,000 mg daily, and clofazimine 100 mg daily)
Number of subjects: 106
Study: 7505008

Group type: EXPERIMENTAL
Intervention: Intrinsic asthma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epithelial ICAM‐1 expression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allergen challenge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epithelial ICAM‐1 expression after allergen challenge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VCAM‐1 and ICAM‐1 expression after allergen challenge
Number of subjects: 0
Study: 2881786

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (0.1-0.2 microgram kg-1 min-1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Pindolol (beta-adrenergic blocker)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Practolol (beta-adrenergic blocker)
Number of subjects: 7
Study: 30223721

Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulation therapy
Number of subjects: 46
Study: 27504914

Group type: EXPERIMENTAL
Intervention: adalimumab 40 mg every-other-week (following a single 80 mg dose)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: adalimumab (any time during the study)
Number of subjects: 425
Study: 26422980

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Sham electrical stimulation
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: PTNS
Number of subjects: 227

Group type: COMPARATOR
Intervention: PTNS and Sham
Number of subjects: 227
Study: 23555855

Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT) for 16 weeks (20 minutes three times per week)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Active Control (AC) program of equal length and structure, involving viewing short documentaries about the natural world
Number of subjects: 135
Study: 22100175

Group type: EXPERIMENTAL
Intervention: B-Twin® spacer
Number of subjects: 50

Group type: COMPARATOR
Intervention: Corset
Number of subjects: 50
Study: 19404392

Group type: EXPERIMENTAL
Intervention: Daily acyclovir for genital herpes (HSV-2) suppression
Number of subjects: 3408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3408
Study: 17525360

Group type: EXPERIMENTAL
Intervention: Facial sensory re-training exercises
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard opening exercises (Control)
Number of subjects: 100
Study: 15383110

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (diamorphine 1.2 mg loading dose intravenously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular diamorphine (as per hospital protocol)
Number of subjects: 0
Study: 11149996

Group type: EXPERIMENTAL
Intervention: Grass pollen immunotherapy (n = 22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 44
Study: 10432871

Group type: EXPERIMENTAL
Intervention: Brand B (best manufacture)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gloves worn longer than 2 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgeons
Number of subjects: 0

Group type: COMPARATOR
Intervention: Others
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subjects with allergy history
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subjects without allergy history
Number of subjects: 0
Study: 7584951

Group type: EXPERIMENTAL
Intervention: Cationic liposome complexed with CFTR cDNA
Number of subjects: 15

Group type: COMPARATOR
Intervention: Liposome only (control)
Number of subjects: 15
Study: 2407813

Group type: EXPERIMENTAL
Intervention: Adjuvant single-agent chemotherapy with doxorubicin
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: None or one risk factor
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Two risk factors
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Three risk factors
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Four and five risk factors
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Three factors or less
Number of subjects: 148
Study: 7001863

Group type: EXPERIMENTAL
Intervention: Thiazide diuretics (bendroflumethiazide, chlorthalidone, hydrochlorothiazide)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Loop diuretics (bumetanide, furosemide, triamterene)
Number of subjects: 18
Study: 31027477

Group type: EXPERIMENTAL
Intervention: Peer coaching with iDecide (interactive web-based tool)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Peer coaching with nontailored educational materials
Number of subjects: 290
Study: 28905377

Group type: EXPERIMENTAL
Intervention: Group prenatal care (PNC)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Individual prenatal care (PNC)
Number of subjects: 193
Study: 25791173

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (Tisseel) applied to the uterine cervix (2 ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no fibrin sealant)
Number of subjects: 40
Study: 23403384

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 207

Group type: COMPARATOR
Intervention: Everolimus-eluting stent
Number of subjects: 207
Study: 20801938

Group type: EXPERIMENTAL
Intervention: Riociguat (2.5 mg, 3 times daily for 10 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Warfarin (25 mg single oral dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19525733

Group type: EXPERIMENTAL
Intervention: Visual Activities Questionnaire (VAQ)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: National Eye Institute-Visual Function Questionnaire (NEI-VFQ)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Visual Activities Questionnaire (VAQ) and National Eye Institute-Visual Function Questionnaire (NEI-VFQ)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Clinical measures of visual function
Number of subjects: 426

Group type: COMPARATOR
Intervention: Visual field (VF) loss
Number of subjects: 426
Study: 17138821

Group type: EXPERIMENTAL
Intervention: Standard intensity FAB/LMB therapy
Number of subjects: 190

Group type: COMPARATOR
Intervention: Reduced intensity therapy (reduced cytarabine plus etoposide and deletion of 3 maintenance courses M2, M3, M4)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Combined BM/CNS disease at diagnosis or poor response to COP reduction therapy
Number of subjects: 190
Study: 14500060

Group type: EXPERIMENTAL
Intervention: Peer-led sex education
Number of subjects: 29

Group type: COMPARATOR
Intervention: Teacher-led sex education (Control)
Number of subjects: 29
Study: 10872909

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (1%) in vaginal hydrophilic gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8843042

Group type: EXPERIMENTAL
Intervention: Moderate exercise (three 40‐min sessions of brisk walking a week for 6 months)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 177